{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:15:37Z","timestamp":1788236137145,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After bilateral lung transplantation for interstitial lung disease (ILD), most recipients recover well, but some deteriorate over the following years. The C-reactive protein\u2013to\u2013albumin ratio (CAR) combines a marker of systemic inflammation (CRP) with one of nutritional and hepatic-synthetic reserve (albumin); a rising ratio reflects worsening inflammation against falling reserve. We assessed whether tracking CAR over time identifies the subgroup at risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied 138 consecutive adult ILD recipients of bilateral lung transplants (Giessen, 2000 to 2026), with a median of 13 paired CRP and albumin measurements each. Using group-based trajectory modelling, we grouped patients by the trajectory of their CAR from the first routine follow-up visit (month 4) to year 5, then related the groups to five-year survival and the Clinical Frailty Scale (CFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three CAR trajectories emerged. Most patients were stable-low (39%, CAR near zero throughout) or resolving (38%, initially high then falling). The key group was CAR-rising (23%): at four months these patients were indistinguishable from the best-recovering stable-low group but then climbed steadily over the following years. Five-year survival was 92%, 61% and 69% in the stable-low, rising and resolving groups (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029; rising versus stable-low hazard ratio 4.5, 95% CI 1.2 to 17.1). A landmark analysis among patients alive at year 2 confirmed this late risk: 33% of the rising group died over the next three years versus 5% of the stable-low group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). In the pre-specified model, phenotype membership was not predicted by ILD subtype or LAS at listing (likelihood-ratio\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.16); pre-transplant CAR itself differed modestly across the groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049) but was not prognostic for survival. The CFS trajectory, scored independently of CRP and albumin, showed the same pattern: groups were equally frail before transplant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.83) but separated afterwards (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01 at 4 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001 at 5 years), the adverse groups drifting back toward frailty.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A simple test already measured at every post-transplant visit, the CRP-to-albumin ratio, can be read as a trajectory to identify the ILD recipients who enter an inflammatory and nutritional decline associated with worse five-year survival. These findings are hypothesis-generating, and further work is needed to establish what drives the CAR trajectory before any clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The analysis draws on two registries: the European IPF Registry and Biobank (eurIPFreg; ClinicalTrials.gov NCT02951416, registered 1 November 2016) and the European ILD Registry and Biobank (eurILDreg; German Clinical Trials Register DRKS00028968, registered 26 July 2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04648-7","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:14:43Z","timestamp":1788232483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-transplant trajectories of the CRP-to-albumin ratio identify a late-emerging high-risk phenotype in interstitial lung disease"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-4294","authenticated-orcid":false,"given":"Ekaterina","family":"Krauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Sommerlad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gani","family":"Oruqaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kuhnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"4","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"01565","DOI":"10.1183\/23120541.01565-2025","volume":"12","author":"S Kuhnert","year":"2026","unstructured":"Kuhnert S, Guler S, Wilke L, Sommerlad J, Tello S, Windhorst A, et al. Peri-transplant frailty changes impact survival in interstitial lung diseases. ERJ Open Res. 2026;12(4):01565\u20132025. https:\/\/doi.org\/10.1183\/23120541.01565-2025.","journal-title":"ERJ Open Res"},{"issue":"5","key":"4648_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489\u201395.","journal-title":"CMAJ"},{"issue":"4","key":"4648_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/jcm9041236","volume":"9","author":"M Bender","year":"2020","unstructured":"Bender M, Haferkorn K, Friedrich M, Uhl E, Stein M. Impact of early C-reactive protein\/albumin ratio on intra-hospital mortality among patients with spontaneous intracerebral hemorrhage. J Clin Med. 2020;9(4):1236.","journal-title":"J Clin Med"},{"issue":"3","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"e59321","DOI":"10.1371\/journal.pone.0059321","volume":"8","author":"OT Ranzani","year":"2013","unstructured":"Ranzani OT, Zampieri FG, Forte DN, Pontes Azevedo LC, Park M. C-reactive protein\/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE. 2013;8(3):e59321.","journal-title":"PLoS ONE"},{"issue":"10","key":"4648_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/jcm7100333","volume":"7","author":"JE Park","year":"2018","unstructured":"Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY, et al. The C-reactive protein\/albumin ratio as a predictor of mortality in critically ill patients. J Clin Med. 2018;7(10):333.","journal-title":"J Clin Med"},{"issue":"4","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.17085\/apm.22176","volume":"17","author":"KS Kim","year":"2022","unstructured":"Kim KS, Kwon HM, Kim JH, Yang JW, Jun IG, Song JG, et al. C-reactive protein-to-albumin ratio is a predictor of 1-year mortality following liver transplantation. Anesth Pain Med (Seoul). 2022;17(4):420\u20138.","journal-title":"Anesth Pain Med (Seoul)"},{"issue":"17","key":"4648_CR7","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2011.03.028","volume":"47","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O\u2019Reilly DSJ, et al. An inflammation-based prognostic score (mGPS) and survival in patients with cancer: a retrospective study of 27,031 patients. Eur J Cancer. 2011;47(17):2633\u201341.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):141.","journal-title":"Respir Res"},{"issue":"1","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12890-024-03389-9","volume":"24","author":"E Krauss","year":"2024","unstructured":"Krauss E, Tello S, Naumann J, Wobisch S, Ruppert C, Kuhn S, et al. Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg). BMC Pulm Med. 2024;24(1):572.","journal-title":"BMC Pulm Med"},{"issue":"9","key":"4648_CR10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"4648_CR11","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/jcm14186420","volume":"14","author":"S Kuhnert","year":"2025","unstructured":"Kuhnert S, Wilke L, Sommerlad J, Yogeswaran A, Husain-Syed F, Hecker M, et al. Dual impacts of lung transplantation on the recovery and comorbidity of interstitial lung diseases: a longitudinal assessment of the benefits and burden. J Clin Med. 2025;14(20):6420.","journal-title":"J Clin Med"},{"key":"4648_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109\u201338.","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw. 2017;78(2):1\u201356.","journal-title":"J Stat Softw"},{"issue":"4","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/jcm14041093","volume":"14","author":"P Ntiamoah","year":"2025","unstructured":"Ntiamoah P, Mehta AC. Beyond the graft: recurrence of interstitial lung diseases post transplant. J Clin Med. 2025;14(4):1093.","journal-title":"J Clin Med"},{"issue":"2","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"00038","DOI":"10.1183\/23120541.00038-2022","volume":"8","author":"D Rama Esendagli","year":"2022","unstructured":"Rama Esendagli D, Ntiamoah P, Kupeli E, Bhardwaj A, Ghosh S, Mukhopadhyay S, et al. Recurrence of primary disease following lung transplantation. ERJ Open Res. 2022;8(2):00038\u20132022.","journal-title":"ERJ Open Res"},{"issue":"8","key":"4648_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/ajt.14873","volume":"18","author":"JP Singer","year":"2018","unstructured":"Singer JP, Diamond JM, Anderson MR, Katz PP, Bui S, Lai JC, et al. Frailty phenotypes and mortality after lung transplantation: a prospective cohort study. Am J Transpl. 2018;18(8):1995\u20132004.","journal-title":"Am J Transpl"},{"issue":"7","key":"4648_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.healun.2019.03.006","volume":"38","author":"A Venado","year":"2019","unstructured":"Venado A, McCulloch C, Greenland JR, Katz PP, Schwedhelm S, Christie JD, et al. Frailty trajectories in adult lung transplantation: a cohort study. J Heart Lung Transpl. 2019;38(7):699\u2013707.","journal-title":"J Heart Lung Transpl"},{"issue":"2","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17476348.2020.1702527","volume":"14","author":"E Montgomery","year":"2020","unstructured":"Montgomery E, Macdonald PS, Newton PJ, Chang S, Wilhelm K, Jha SR, et al. Frailty in lung transplantation: a systematic review. Expert Rev Respir Med. 2020;14(2):219\u201327.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.chest.2023.01.017","volume":"164","author":"AC Swaminathan","year":"2023","unstructured":"Swaminathan AC, McConnell A, Peskoe S, Bryant AJ, Reynolds JM, Hartwig MG, et al. Evaluation of frailty measures and short-term outcomes after lung transplantation. Chest. 2023;164(1):159\u201368.","journal-title":"Chest"},{"issue":"3","key":"4648_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.chest.2024.02.043","volume":"166","author":"SA Guler","year":"2024","unstructured":"Guler SA, Marinescu DC, Cox G, Durand C, Fisher JH, Hambly N, et al. The Clinical Frailty Scale for risk stratification in patients with fibrotic interstitial lung disease. Chest. 2024;166(3):517\u201327.","journal-title":"Chest"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04648-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:30:42Z","timestamp":1788233442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04648-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The eurIPFreg\/eurILDreg operates under ethical approval from the Ethics Committee of the Justus-Liebig University Giessen (approval no. 111\/08). eurIPFreg is registered at ClinicalTrials.gov (NCT02951416; registered 1 November 2016) and eurILDreg in the German Clinical Trials Register (DRKS00028968; registered 26 July 2022); both registries were registered after enrolment of the first participants. All study procedures comply with the principles of the Declaration of Helsinki. All transplant recipients included in this analysis provided written informed consent for participation and for the use and publication of their pseudonymised data. The transplanted organs were provided by deceased donors and were allocated through Eurotransplant in accordance with the German Transplantation Act (Transplantationsgesetz), under which consent for donation is obtained within the statutory framework; donors were not participants in this study, and no donor-identifying information was collected or analysed. The only donor-related variable used, graft cold ischaemia time, is a routine operative parameter that does not identify the donor.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript reports only aggregated, de-identified data and contains no images or individual-level clinical details from which any participant could be identified. Written informed consent covering the use and publication of pseudonymised data was nonetheless obtained from all participants at registry enrolment (see Ethics approval and consent to participate).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"390"}}